RxDoctor Payments Data

Madelyn Holzman, MD

Urology · Chico, CANPI 1184624769

Payments from drug & device makers

$3,285in general payments, 2019–2025

Across 64 payments — averaging $51.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$2K
  • Astellas Pharma US Inc$418
  • Johnson & Johnson$270
  • Procept Biorobotics Corporation$185
  • Merck$133
  • Sumitomo Pharma America, Inc.$99
  • plus $385 from 9 others

What the payments were for

  • Food & beverage$3,10194%
  • Education$1846%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,285 in reported general payments places this provider in the 55th percentile of 1,324 urology providers in California.

See all urology providers in California

Medicare billing

Part B allowed, 2024
$442,631
Medicare patients
714
Services billed
13,130

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide12$171,517
MyrbetriqMirabegron35$22,578
Oxybutynin Chloride ErOxybutynin Chloride456$11,954
Tamsulosin Hcl296$3,269
Fesoterodine Fumarate ErFesoterodine Fumarate32$2,219
Estradiol25$2,163
NitrofurantoinNitrofurantoin Macrocrystal90$2,159
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst25$1,191
Oxybutynin Chloride63$1,130
Finasteride42$557
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim104$522
Levofloxacin81$366
Testosterone Cypionate16$348
Cephalexin73$231
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen28$152

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$418$194,09547 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,324 urology providers in California.

Other urology in Chico

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →